Clinical Trials
4 trialsNCT02182622 2019-06-19
LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel
Hackensack Meridian Health
Phase 1 Withdrawn
NCT01911416 2016-06-09
A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer
University of Utah
Phase NA Withdrawn
NCT01757327 2015-04-27
LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer
Washington University School of Medicine
Phase 2 Withdrawn
NCT01694589 2014-12-12
A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer
Rutgers, The State University of New Jersey
Phase EARLY_PHASE1 Withdrawn